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Foreword
As the largest organ of the body, the skin performs multiple critical functions, such as 
serving as the primary barrier to the external environment. For this reason, the skin is 
often exposed to potentially hazardous agents, including chemicals, which may contribute 
to the onset of a spectrum of adverse health effects ranging from localized damage (e.g., 
irritant contact dermatitis and corrosion) to induction of immune-mediated responses 
(e.g., allergic contact dermatitis and pulmonary responses), or systemic toxicity (e.g., 
neurotoxicity and hepatoxicity). Understanding the hazards related to skin contact with 
chemicals is a critical component of modern occupational safety and health programs.
In 2009, the National Institute for Occupational Safety and Health (NIOSH) pub-
lished Current Intelligence Bulletin (CIB) 61: A Strategy for Assigning New NIOSH Skin 
Notations [NIOSH 2009–147]. This document provides the scientific rationale and 
framework for the assignment of multiple hazard-specific skin notations (SK) that 
clearly distinguish between the systemic effects, direct (localized) effects, and immune- 
mediated responses caused by skin contact with chemicals. The key step within assign-
ment of the hazard-specific SK is the determination of a substance’s hazard potential, or 
its potential for causing adverse health effects as a result of skin exposure. This determi-
nation entails a health hazard identification process that involves use of the following:
 • Scientific data on the physicochemical properties of a chemical
 • Data on human exposures and health effects
 • Empirical data from in vivo and in vitro laboratory testing
 • Computational techniques, including predictive algorithms and mathematical 
models that describe a selected process (e.g., skin permeation) by means of ana-
lytical or numerical methods. 
This Skin Notation Profile provides the SK assignment and supportive data for nitro-
glycerin (CAS No. 55-63-8). In particular, this document evaluates and summarizes the 
literature describing the substance’s hazard potential and its assessment according to the 
scientific rationale and framework outlined in CIB 61. In meeting this objective, this 
Skin Notation Profile intends to inform the audience—mostly occupational health prac-
titioners, researchers, policy- and decision-makers, employers, and workers in potentially 
hazardous workplaces—so that improved risk-management practices may be developed 
to better protect workers from the risks of skin contact with the chemical of interest.
John Howard, M.D. 
Director, National Institute for  
 Occupational Safety and Health 
Centers for Disease Control and Prevention
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Abbreviations
ACGIH American Conference of Governmental Industrial Hygienists 
CIB Current Intelligence Bulletin
cm2 square centimeter(s)
cm/hr centimeter(s) per hour
DEREK™ Deductive Estimation of Risk from Existing Knowledge
DIR skin notation indicating the potential for direct effects to the skin 
   following contact with a chemical
EC European Commission 
(FATAL) subnotation of SK: SYS indicating chemicals are highly or extremely 
   toxic and may be potentially lethal or life-threatening following 
   exposure of the skin
GHS Globally Harmonized System of Classification and Lebeling of Chemicals
GPMT guinea pig maximization test
IARC International Agency for Research on Cancer
(IRR) subnotation of SK: DIR indicating the potential for a chemical to be a 
   skin irritant following exposure to the skin
Kaq  coefficient in the watery epidermal layer 
Kp skin permeation coefficient 
Kpol  coefficient in the protein fraction of the stratum corneum
Kpsc  permeation coefficient in the lipid fraction of the stratum corneum 
LD50  dose resulting in 50% mortality in the exposed population
LDLo dermal lethal dose
log KOW base-10 logarithm of a substance’s octanol–water partition
m3 cubic meter(s)
mg milligram(s)
mg/cm2/hr  milligram(s) per square centimeter per hour
mg/hr milligram(s) per hour
mg/mL milligram(s) per milliliter
mg/kg/day milligram(s) per kilogram body weight per day
mg/m3 milligram(s) per cubic meter
MW molecular weight
NIOSH National Institute for Occupational Safety and Health
nmol/cm2/hr namomoles per square centimeter per hour
NOAEL no-observed-adverse-effect level
NTP National Toxicology Program
OEL occupational exposure limit
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OSHA Occupational Safety and Health Administration
REL recommended exposure limit
RF retention factor 
SEN skin notation indicating the potential for immune-mediated reactions 
   following exposure of the skin
SI ratio ratio of skin dose to inhalation dose
SK skin notation
SW  solubility 
SYS skin notation indicating the potential for systemic toxicity following 
   exposure of the skin
TTSs transcutaneous therapeutic systems
USEPA United States Environmental Protection Agency 
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Glossary 
Absorption—The transport of a chemical from the outer surface of the skin into both 
the skin and systemic circulation (including penetration, permeation, and resorption). 
Acute exposure—Contact with a chemical that occurs once or for only a short period 
of time. 
Cancer—Any one of a group of diseases that occurs when cells in the body become 
abnormal and grow or multiply out of control. 
Contaminant—A chemical that is (1) unintentionally present within a neat substance 
or mixture at a concentration less than 1.0% or (2) recognized as a potential carcinogen 
and present within a neat substance or mixture at a concentration less than 0.1%. 
Cutaneous (or percutaneous)—Referring to the skin (or through the skin). 
Dermal—Referring to the skin. 
Dermal contact—Contact with (touching) the skin. 
Direct effects—Localized, non-immune-mediated adverse health effects on the skin, 
including corrosion, primary irritation, changes in skin pigmentation, and reduction/
disruption of the skin barrier integrity, occurring at or near the point of contact with 
chemicals. 
Immune-mediated responses—Responses mediated by the immune system, including 
allergic responses. 
Sensitization—A specific immune-mediated response that develops following expo-
sure to a chemical, which, upon re-exposure, can lead to allergic contact dermatitis 
(ACD) or other immune-mediated diseases such as asthma, depending on the site and 
route of re-exposure. 
Substance—A chemical. 
Systemic effects—Systemic toxicity associated with skin absorption of chemicals after 
exposure of the skin.
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1.2 Purpose
This Skin Notation Profile presents (1) a 
brief summary of technical data associ-
ated with skin contact with nitroglycerin 
and (2) the rationale behind the hazard-
specific skin notation (SK) assignment 
for nitroglycerin. The SK assignment is 
based on the scientific rationale and logic 
outlined in the Current Intelligence Bulle-
tin (CIB) 61: A Strategy for Assigning New 
NIOSH Skin Notations [NIOSH 2009]. 
The summarized information and health 
hazard assessment are limited to an evalu-
ation of the potential health effects of der-
mal exposure to nitroglycerin. A literature 
search was conducted through July 2010 
to identify information on nitroglycerin, 
including but not limited to data relating 
to its toxicokinetics, acute toxicity, repeat-
ed-dose systemic toxicity, carcinogenic-
ity, biological system/function–specific 
effects (including reproductive and de-
velopmental effects and immunotoxicity), 
irritation, and sensitization. Information 
was considered from studies of humans, 
animals, or appropriate modeling systems 
that are relevant to assessing the effects of 
dermal exposure to nitroglycerin.
1.3 Overview of SK Assignment 
for Nitroglycerin
Nitroglycerin is potentially capable of 
causing multiple adverse health effects 
following skin contact. A critical review of 
available data has resulted in the follow-
ing SK assignment for nitroglycerin: SK: 
SYS (FATAL)-DIR (IRR)-SEN. Table 1 
provides an overview of the critical effects 
and data used to develop the SK assign-
ment for nitroglycerin.
2 Systemic Toxicity from Skin 
Exposure (SK: SYS)
Numerous studies following human dermal 
exposure to nitroglycerin were identified. A 
1 Introduction
1.1 General Substance Information
Chemical: Nitroglycerin
CAS No: 55–63–8
Synonyms:
Glyceryl Trinitrate; NG; 
1,2,3- Propanetriol Trinitrate; 
 Trinitroglycerin
Molecular weight (MW): 227.09
Molecular formula: C3H5N3O9
Structural formula:
O
N+
N+
O-
O-
N+
O-
O
O
O
O
O
Uses:
Nitroglycerin is an organic nitrate ester 
substance used primarily in the produc-
tion of explosives and as a vasodilating 
pharmaceutical agent [NIOSH 1978]. 
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nitroglycerin transdermal system is exten-
sively used to prevent and treat angina pec-
toris (suffocating chest pain); the rate of re-
lease of nitroglycerin is linearly dependent 
upon the area of the applied system [No-
vartis Pharmaceutical Corporation 2000]. 
Although the percent dermal absorption of 
nitroglycerin was not included in the reports 
of any of these studies, there is evidence that 
the substance is absorbed through the skin 
of humans following dermal exposure. This 
evidence is measurements of nitroglycerin 
concentration in the blood of exposed work-
ers or the onset of systemic effects following 
use of nitroglycerin in transdermal systems 
or as ointment in the treatment of chest 
pain. For example, Schwartz [1946] report-
ed that nitroglycerin was readily absorbed 
through the intact human skin in amounts 
sufficient to cause vasodilation. Several 
studies have revealed increases in blood ni-
troglycerin levels in humans following ap-
plication of the substance in ointment or 
nonointment transdermal systems, indicat-
ing that nitroglycerin is dermally absorbed 
[Wester et al. 1959; Blumenthal et al. 1977; 
Sved et al. 1981; Colfer et al. 1982; Muller 
et al. 1982; Iafrate et al. 1983; McAllister et 
al. 1986]. Gjesdal et al. [1985] and Sivertsen 
[1984] measured nitroglycerin concentra-
tions in the plasma of 12 volunteers before 
and during the production of gun powder. 
The reported results included detection of 
a higher nitroglycerin concentration in the 
cubital vein than in the femoral vein in ex-
posed workers, suggesting significant local 
absorption of nitroglycerin through the 
skin of the hands and arms despite the use 
of protective clothing. Crandell et al. [1929] 
estimated a human skin permeability coeffi-
cient of 1.1 × 10-2 centimeter per hour (cm/
hr). The potential of nitroglycerin to pose a 
skin absorption hazard was also evaluated, 
with use of a predictive algorithm for esti-
mating and evaluating the health hazards 
of dermal exposure to substances [NIOSH 
2009]. The evaluation method compares an 
estimated dose accumulated in the body 
from skin absorption and an estimated dose 
from respiratory absorption associated with 
a reference occupational exposure limit. On 
the basis of this algorithm, a ratio of the 
skin dose to the inhalation dose (SI ratio) 
of 4.97 was calculated for nitroglycerin. An 
SI ratio of ≥0.1 indicates that a chemical is 
capable of producing systemic toxicity from 
skin exposure [NIOSH 2009]. Additional 
information on the SI ratio and the vari-
ables used in its calculation are included in 
the appendix.
Quantitative estimates of dermal absorp-
tion have been provided in several ani-
mal studies. Wester et al. [1959] reported 
that nitroglycerin was readily absorbed 
through the skin of rhesus monkeys; the 
absolute bioavailability was reported to be 
56.6% following topical application in an 
ointment. Kikkoji et al. [1991] reported a 
permeability coefficient for nitroglycerin 
of 20 × 10-3 cm/hr when it is applied as an 
aqueous solution and 1.6 × 10-3 cm/hr when 
Table 1. Summary of the SK assignment for nitroglycerin
Skin Notation Critical Effect Data Available
SK: SYS (FATAL) Circulatory/vascular effects 
(development of vascular 
tolerance); developmental 
effects 
Sufficient human and animal data
SK: DIR (IRR) Skin irritation Sufficient human and animal data
SK: SEN Skin sensitization Limited human and animal data
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itroglycerinit is applied as an ointment. Those authors 
used a full-thickness hairless mouse skin 
in vitro. These investigators also reported 
a steady-state flux of 154 nanomoles per 
square centimeter per hour (nmol/cm2/
hr)—corresponding to 0.04 milligram per 
square centimeter per hour (mg/cm2/hr)—
in the mouse following application of ni-
troglycerin in ointment formulation. The 
available findings from in vivo and in vitro 
studies in both humans and animals show 
that nitroglycerin can be absorbed through 
the skin.
No dermal lethal concentration (LDLo) 
for humans has been identified. No reli-
able dermal LD50 value (the dose resulting 
in 50% mortality in the exposed popula-
tion) has been identified for experimental 
animals, precluding adequate evaluation 
of the potential for acute dermal toxicity. 
Several epidemiologic studies were identi-
fied [Schwartz 1946; Bresler 1949; Hanlon 
and Fredrick 1966; Lund et al. 1968; Lange 
et al. 1972; Hogstedt and Andersson 1979] 
that revealed results such as mortality and 
chronic vascular effects (i.e., headache, 
blood pressure changes, chest pain, and 
electroencephalographic changes) in work-
ers exposed to nitroglycerin. However, 
these studies involved both inhalation and 
dermal exposures. Robinson et al. [2001] 
reported effects on systemic vascular tone, 
as evidenced by decreased diastolic blood 
pressure and pulse pressure and increased 
heart rate following topical application of 
2% nitroglycerin ointment. These inves-
tigators indicated that the cardiovascular 
responses did not cause unexpected side 
effects, except that three of four volunteers 
had headaches after the experiments. For 
treatment of chest pain, Novartis Pharma-
ceutical Corporation [2000] suggested a 
starting dose of nitroglycerin between 0.2 
mg/hr and 0.4 milligram per hour (mg/
hr); doses between 0.4 mg/hr and 0.8 mg/
hr [corresponding to approximately 0.06 to 
0.14 milligram per kilogram per day (mg/
kg/day) for a 70-kg person] showed con-
tinued effectiveness for 10 to 12 hours daily 
for at least one month (the longest period 
studied) of intermittent administration. 
This implies that the no-observed-adverse-
effect level (NOAEL) ranges between 0.06 
and 0.14 mg/kg/day in humans and that 
dermal doses higher than the therapeutic 
doses are likely to result in systemic (car-
diovascular) effects. Because the therapeu-
tic doses and the rabbit NOAEL are much 
lower than the critical dermal NOAEL 
value of 1000 mg/kg/day that identifies 
chemical substances with the potential for 
repeated-dose dermal toxicity [NIOSH 
2009], nitroglycerin is considered systemi-
cally available and can cause systemic ef-
fects following dermal exposure. 
Immediate removal of workers from long-
term exposures to nitroglycerin has re-
sulted in life-threatening health effects 
and deaths [NIOSH 1978; Hogstedt and 
Andersson 1979]. Workers subchronically 
or chronically exposed to nitroglycerin 
develop a tolerance to effects of the vaso-
dilating action of the substance, resulting 
in a semipermanently altered health state 
characterized by blood pressure chang-
es and compensatory vasoconstriction 
[NIOSH 1978; Abrams 1980]. With-
drawal from exposure to the vasodilating 
agent (i.e., on a weekend or holiday leave) 
has been associated with angina pectoris 
and death caused by continued vascu-
lar tolerance in the absence of the nitro-
glycerin [NIOSH 1978]. Because of the 
potential for sudden death, removal from 
exposure should not be abrupt.
No standard toxicity or specialty studies 
evaluating biological system/function–
specific effects (including reproductive ef-
fects and immunotoxicity) in humans fol-
lowing dermal exposure to nitroglycerin 
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were identified. Novartis Pharmaceutical 
Corporation [2000] indicated that in a 
teratology study, nitroglycerin topically ap-
plied to rats at doses up to 80 mg/kg/day 
and to rabbits at doses up to 240 mg/kg/
day did not result in toxic effects on dams 
or fetuses. However, ProStrakan [2007] 
reported that nitroglycerin was fetotoxic 
(causing decreased birth weights) in rats 
after in utero exposure during fetal devel-
opment at dermal dosages above 28 mg/
kg/day, indicating that nitroglycerin is a 
developmental toxicant with a NOAEL of 
28 mg/kg/day. Table 2 summarizes carci-
nogenic designations by multiple govern-
mental and nongovernmental organiza-
tions for nitroglycerin.
Taken together, the available toxicoki-
netic data from studies of humans and 
animals [Wester et al. 1959; Gjesdal et 
al. 1985; McAllister et al. 1986; Kikkoji 
et al. 1991*] and from the pharmaceuti-
cal use of nitroglycerin [Novartis Phar-
maceutical Corporation 2000] are suf-
ficient to conclude that nitroglycerin can 
penetrate the skin and be absorbed in 
sufficient amounts to cause circulatory, 
vascular, gastrointestinal, or kidney effects, 
death, or fetal effects. In addition, suffi-
cient evidence is available to indicate that 
abrupt withdrawal of workers from long-
term exposure to nitroglycerin may result 
in deaths because of continued vascular 
tolerance [NIOSH 1978; Hogstedt and 
Andersson 1979; Abrams 1980]. There-
fore, on the basis of the data for this as-
sessment, nitroglycerin is assigned the SK: 
SYS (FATAL) notation.
3 Direct Effect(s) on Skin  
(SK: DIR)
No data on corrosivity of nitroglycerin from 
in vitro tests with human or animal skin 
models or on skin integrity with cadaver skin 
were identified. However, several case re-
ports have noted skin irritation reactions (ir-
ritant contact dermatitis) as cutaneous side 
effects in patients exposed to nitroglycerin 
transcutaneous therapeutic systems (TTSs) 
or patches [Muller et al. 1982; Fischer and 
Tyler 1985; Kapoor et al. 1985; Schrader et 
al. 1986; Carmichael and Foulds 1989; Vail-
lant et al. 1990; Kounis et al. 1996]. These 
reactions are mostly in the form of burning, 
Table 2. Summary of the carcinogenic designations* for nitroglycerin by 
numerous governmental and nongovernmental organizations
Organization Carcinogenic designation 
NIOSH [2005] None
NTP [2009] None
USEPA [2010] Group D: Not classifiable as to human carcinogenicity 
IARC [2009] None
EC [2010] None
ACGIH [2001] None
Abbreviations: ACGIH = American Conference of Governmental Industrial Hygienists; EC = European Commission, Joint Re-
search, Institute for Health and Consumer Protection; IARC = International Agency for Research on Cancer; NIOSH = National 
Institute for Occupational Safety and Health; NTP = National Toxicology Program; USEPA = United States Environmental 
Protection Agency.
*Note: The listed cancer designations were based on data from nondermal (such as oral or inhalation) exposure rather than der-
mal exposure.
*References in bold text indicate studies that served 
as the basis of the SK assignment.
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itroglycerinpruritus, and erythema that appear in the 
area of the patch placement. Nitroglycerin 
was a very mild skin irritant in rabbits [Lee 
et al. 1975]. The structure-activity relation-
ship model, Deductive Estimation of Risk 
from Existing Knowledge (DEREK™) 
for Windows, predicted nitroglycerin to be 
negative for skin irritation. 
Case reports [Vaillant et al. 1990; Kounis 
et al. 1996] demonstrate that prolonged 
and repeated dermal exposure to nitro-
glycerin ointment or transdermal nitro-
glycerin products can result in irritant 
contact dermatitis. Although the irritant 
symptoms observed could possibly reflect 
other ingredients in the ointments or fac-
tors related to the conditions of dosing in 
the clinical studies, animal studies [Lee 
et al. 1975] provide supporting evidence 
that nitroglycerin itself is mildly irritating 
to rabbit skin. Therefore, on the basis of 
the data for this assessment, nitroglycerin 
is assigned the SK: DIR (IRR) notation.
4 Immune-mediated 
Responses (SK: SEN)
Several studies were identified that evalu-
ated the potential of nitroglycerin to cause 
skin sensitization. Vaillant et al. [1990] re-
ported a prospective study in which 33 pa-
tients using transdermal nitroglycerin for 
more than 7 days tested negative in patch 
tests with nitroglycerin, even though 5 pa-
tients (15%) had adverse reactions (burn-
ing sensation, sweating, itching, severe 
erythema, and erythematous vesicular le-
sions). Kounis et al. [1996] assessed cuta-
neous reactions to nitroglycerin in a study 
involving continuous and intermittent use 
of three different commercially available 
nitroglycerin TTSs by 320 subjects. Four 
(1.2%) of these subjects developed local-
ized and remote skin reactions. Three of 
the four subjects were patch-tested and 
had positive reactions to both a nitroglyc-
erin solution [0.2 milligram per milliliter 
(mg/mL)] and a nitroglycerin ointment 
(concentration not reported). Other case 
reports described individuals who present-
ed with or without dermatitis from topical 
use of a nitroglycerin TTS or nitroglycerin 
ointment and developed allergic reactions 
when patch-tested with nitroglycerin, 
nitroglycerin delivered in TTS, or nitro-
glycerin solutions [Sausker and Frederick 
1978; Zugerman et al. 1979; Hendricks 
and Dec 1979; Rosenfeld and White 1984; 
Fischer and Tyler 1985; Topaz and Abra-
ham 1987; Silvestre et al. 1991; Kanerva 
et al. 1991; Torres et al. 1992; Kounis et 
al. 1996; Machet et al. 1999; Perez-Calde-
ron et al. 2002]. Aquilina et al. [2002] 
reported a single case of cross-sensitive 
contact reaction to nitroglycerin (applied 
in a transdermal patch) following intra-
venous therapy with isosorbide dinitrate. 
Nitroglycerin was also reported to cause 
moderate skin sensitization in one guinea 
pig maximization test (GPMT) [Lee et al. 
1975]. DEREK™ predicted nitroglycerin 
to be negative for skin sensitization.
Although nitroglycerin yielded negative 
patch-test results in some prospective 
studies [Vaillant 1990; Velez et al. 1992; 
Stanford and Georgouras 1996], find-
ings from patch tests in humans present-
ing with or without dermatitis after use 
of topical or transdermal nitroglycerin 
products [Sausker and Frederick 1978; 
Zugerman et al. 1979; Hendricks and 
Dec 1979; Rosenfeld and White 1984; 
Fischer and Tyler 1985; Topaz and Abra-
ham 1987; Silvestre et al. 1991; Kanerva 
et al. 1991; Torres et al. 1992; Kounis 
et al. 1996; Machet et al. 1999; Perez-
Calderon et al. 2002] and from a GPMT 
[Lee et al. 1975] provide limited evidence 
that prolonged and repeated contact with 
nitroglycerin may cause allergic contact 
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responses. Therefore, on the basis of the 
data for this assessment, nitroglycerin is 
assigned the SK: SEN notation. 
5 Summary
The available toxicokinetic data from stud-
ies of both humans and animals [Wester 
et al. 1959; Gjesdal et al. 1985; McAl-
lister et al. 1986; Kikkoji et al. 1991] in-
dicate that nitroglycerin can be absorbed 
through the skin. The wealth of data relat-
ing to therapeutic use of topically applied 
nitroglycerin indicate that such applica-
tion of nitroglycerin induces systemic ef-
fects such as circulatory or vascular chang-
es and death [Novartis Pharmaceutical 
Corporation 2000]. Developmental stud-
ies indicated that nitroglycerin is fetotoxic 
(causing decreased birth weights) for rats. 
Available data indicate that abrupt with-
drawal of workers from long-term nitro-
glycerin exposure may result in deaths due 
to continued vascular tolerance [NIOSH 
1978; Hogstedt and Andersson 1979; 
Abrams 1980]. Sufficient data are avail-
able from human experience [Vaillant et 
al. 1990; Kounis et al. 1996] and stan-
dard animal studies [Lee et al. 1975] to 
demonstrate that dermal exposures to ni-
troglycerin can cause mild skin irritation. 
Although the incidence of skin sensitiza-
tion in humans appears to be rare (given 
the extensive use of nitroglycerin for pre-
vention and treatment of suffocating chest 
pain), the findings in human patch tests 
[Sausker and Frederick 1978; Zugerman 
et al. 1979; Hendricks and Dec 1979; 
Rosenfeld and White 1984; Fischer and 
Tyler 1985; Topaz and Abraham 1987; 
Silvestre et al. 1991; Kanerva et al. 1991; 
Torres et al. 1992; Kounis et al. 1996; 
Machet et al. 1999; Perez-Calderon et al. 
2002] and one GPMT [Lee et al. 1975] 
provide limited evidence that prolonged 
and repeated use of nitroglycerin can cause 
allergic contact dermatitis. Therefore, on 
the basis of the data for this assessment, 
nitroglycerin is assigned the notation SK: 
SYS (FATAL)-DIR (IRR)-SEN. 
Table 3 summarizes the skin hazard desig-
nations for nitroglycerin previously issued 
by NIOSH and other organizations. The 
equivalent dermal designations for nitro-
glycerin, according to the Global Harmo-
nized System (GHS) of Classification and 
Labeling of Chemicals, are Acute Toxic-
ity Category 1 (Hazard statement: Fatal 
in contact with the skin) and a Category 
2 Repeated Exposure Toxicant (Hazard 
statement: May cause damage to organs 
through prolonged or repeated exposure) 
[European Parliament 2008]. 
Table 3. Summary of the previously issued skin hazard designations for nitroglycerin 
Organization Skin hazard designation 
NIOSH [2005] [skin]: Potential for dermal absorption
OSHA [2010] [skin]: Based on potential contribution to overall exposure by the cuta-
neous route, including the mucous membranes and the eyes, either by 
airborne exposure or, more particularly, direct contact with the substance
ACGIH [2001] [skin]: Based on the potential for dermal absorption and subsequent sys-
temic toxicity
EC [2010] R27: Very toxic in contact with skin
Abbreviations: ACGIH = American Conference of Governmental Industrial Hygienists; EC = European Commission, Joint 
Research, Institute for Health and Consumer Protection; NIOSH = National Institute for Occupational Safety and Health; 
OSHA = Occupational Safety and Health Administration.
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This appendix presents an overview of the 
SI ratio and a summary of the calculation 
of the SI ratio for nitroglycerin. Although 
the SI ratio is considered in the determi-
nation of a substance’s hazard potential 
following skin contact, it is intended only 
to serve as supportive data during the as-
signment of the NIOSH SK. An in-depth 
discussion on the rationale and calculation 
of the SI ratio can be found in Appendix 
B of the Current Intelligence Bulletin (CIB) 
61: A Strategy for Assigning New NIOSH 
Skin Notations [NIOSH 2009]. 
Overview 
The SI ratio is a predictive algorithm for 
estimating and evaluating the health haz-
ards of skin exposure to substances. The al-
gorithm is designed to evaluate the poten-
tial for a substance to penetrate the skin 
and induce systemic toxicity [NIOSH 
2009]. The goals for incorporating this 
algorithm into the proposed strategy for 
assigning the SYS notation are as follows:
1. Provide an alternative method to 
evaluate substances for which no 
clinical reports or animal toxicity 
studies exist or for which empirical 
data are insufficient to determine 
systemic effects.
2. Use the algorithm evaluation re-
sults to determine whether a sub-
stance poses a skin absorption haz-
ard and should be labeled with the 
SYS notation.
The algorithm evaluation includes three 
steps: (1) determining a skin permeation 
coefficient (Kp) for the substance of in-
terest, (2) estimating substance uptake by 
the skin and respiratory absorption routes, 
and  (3) evaluating whether the substance 
poses a skin exposure hazard.
The algorithm is flexible in the data re-
quirement and can operate entirely on the 
basis of the physicochemical properties 
of a substance and the relevant exposure 
parameters. Thus, the algorithm is inde-
pendent of the need for biologic data. Al-
ternatively, it can function with both the 
physicochemical properties and the ex-
perimentally determined permeation co-
efficient when such data are available and 
appropriate for use.
The first step in the evaluation is to deter-
mine the Kp for the substance to describe 
the transdermal penetration rate of the 
substance [NIOSH 2009]. The Kp, which 
represents the overall diffusion of the sub-
stance through the stratum corneum and 
into the blood capillaries of the dermis, is 
estimated from the compound’s molecu-
lar weight (MW) and base-10 logarithm 
of its octanol–water partition coefficient 
(log  KOW). In this example, Kp is deter-
mined for a substance with use of Equa-
tion 1. A self-consistent set of units must 
be used, such as cm/hr, outlined in Table 
A1 Other model-based estimates of Kp 
may also be used [NIOSH 2009].
Equation 1: Calculation of Skin Permeation 
Coefficient (Kp)
where Kpsc is the permeation coefficient in 
the lipid fraction of the stratum corneum, 
Kpol is the coefficient in the protein frac-
tion of the stratum corneum, and Kaq is 
the coefficient in the watery epidermal 
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layer. These components are individually 
estimated by
log Kpsc = −1.326 + 0.6097 × log KOW − 
0.1786 × MW0.5
Kpol = 0.0001519 × MW−0.5
Kaq = 2.5 × MW−0.5
The second step is to calculate the biologic 
mass uptake of the substance from skin 
absorption (skin dose) and inhalation (in-
halation dose) during the same period of 
exposure. The skin dose is calculated as a 
mathematical product of the Kp, the water 
solubility (SW) of the substance, the exposed 
skin surface area, and the duration of ex-
posure. Its units are milligrams (mg). As-
sume that the skin exposure continues for 
8 hours to unprotected skin on the palms 
of both hands (a surface area of 360 cm2). 
Equation 2: Determination of Skin Dose 
Skin dose = Kp × SW × Exposed skin 
surface area × Exposure time
= Kp(cm/hr) × SW (mg/cm3) × 
360 cm2 × 8 hours
The inhalation dose (in mg) is derived 
on the basis of the occupational exposure 
limit (OEL) of the substance—if the OEL 
Table A1. Summary of data used to calculate the SI ratio for nitroglycerin 
Variables used in calculation Units Value
Skin permeation coefficient
Permeation coefficient of stratum corneum lipid 
path(Kpsc)
cm/hr 0.00093
Permeation coefficient of the protein fraction of the 
stratum corneum (Kpol)
cm/hr 1.008 × 10-5
Permeation coefficient of the watery epidermal layer (Kaq) cm/hr 0.16590
Molecular weight (MW)* amu 227
Base-10 logarithm of its octanol–water partition 
coefficient (log KOW)*
None 1.62
Calculated skin permeation coefficient (Kp) cm/hr 0.00094
Skin dose
Water solubility (SW)* mg/cm3 1.38
Calculated skin permeation coefficient (Kp) cm/hr 0.00094
Estimated skin surface area (palms of hand) cm2 360
Exposure time hr 8
Calculated skin dose mg 3.73
Inhalation dose
Occupational exposure limit (OEL)† mg/m3 0.1
Inhalation volume m3 10
Retention factor (RF) None 0.75
Inhalation dose mg 0.75
Skin dose–to–inhalation dose (SI) ratio None 4.97
*Variables identified from SRC [2009].
†The OEL used in calculation of the SI ratio was the NIOSH-recommended exposure limit (REL) [NIOSH 2005].
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systemic effects rather than sensory/irritant 
effects or direct effects on the respiratory 
tract. Assume a continuous exposure of 
8 hours, an inhalation volume of 10 cubic 
meters (m3) inhaled air in 8 hours, and a 
factor of 75% for retention of the airborne 
substance in the lungs during respiration 
(retention factor, or RF).
Equation 3: Determination of Inhalation Dose
Inhalation dose = OEL × Inhalation 
volume × RF
= OEL (mg/m3) × 10 m3 
× 0.75
The final step is to compare the calculated 
skin and inhalation doses and to present 
the result as a ratio of skin dose to inhala-
tion dose (the SI ratio). This ratio quantita-
tively indicates (1) the significance of der-
mal absorption as a route of occupational 
exposure to the substance and (2) the con-
tribution of dermal uptake to systemic tox-
icity. If a substance has an SI ratio greater 
than or equal to 0.1, it is considered a skin 
absorption hazard.
Calculation 
Table A1 summarizes the data applied in 
the previously described equations to de-
termine the SI ratio for nitroglycerin. The 
calculated SI ratio was 4.97. On the basis 
of these results, nitroglycerin is predicted 
to represent a skin absorption hazard.
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